Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression

• John F. Seymour,
• Robert Marcus,
• Andrew Davies,
• Eve Gallop-Evans,
• Andrew Grigg,
• Andrew Haynes,
• Michael Herold,
• Thomas Illmer,
• Herman Nilsson-Ehle,
• Martin Sökler,
• Ulrich Dünzinger,
• Tina Nielsen,
• Aino Launonen,
• Wolfgang Hiddemann

Affiliations

John F. Seymour

Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Victoria, NSW, Australia

Robert Marcus

Kings College Hospital, London, UK

Andrew Davies

Cancer Research UK Centre, University of Southampton, Southampton, UK

Eve Gallop-Evans

Velindre Cancer Centre, Cardiff, UK

Andrew Grigg

Austin Hospital, Melbourne, Victoria, NSW, Australia

Andrew Haynes

Nottingham University Hospitals NHS Trust, Nottingham, UK

Michael Herold

HELIOS-Klinikum Erfurt, Germany

Thomas Illmer

BAG Freiberg-Richter, Jacobasch, Illmer and Wolf, Dresden, Germany

Herman Nilsson-Ehle

Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden

Martin Sökler

Eberhard-Karls-University Tübingen, Tübingen, Germany

Ulrich Dünzinger

Roche Pharma AG, Grenzach-Wyhlen, Germany

Tina Nielsen

F. Hoffmann-La Roche Ltd., Basel, Switzerland

Aino Launonen

F. Hoffmann-La Roche Ltd., Basel, Switzerland

Wolfgang Hiddemann

Department of Medicine III, Ludwig-Maximilians-University, München, Germany